Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1996 Dec;86(12):1709–1712. doi: 10.2105/ajph.86.12.1709

The cost-effectiveness of HIV prevention targeting: how much more bang for the buck?

J G Kahn 1
PMCID: PMC1380721  PMID: 9003125

Abstract

BACKGROUND: Although the targeting of human immunodeficiency virus (HIV) prevention to high-risk populations has been widely discussed, its benefits have not been quantified. METHODS: This analysis of cost-effectiveness combines an HIV epidemic model, target population scenarios, and data on the cost and impact of prevention. RESULTS: The number of HIV infections averted in 5 years with $1 million in annual prevention spending ranges from 164 in high-risk populations to 0.4 in very-low-risk populations. Fortyfold to two-hundredfold differences in prevention costs could equalize HIV infections averted. CONCLUSIONS: Targeting appears to provide substantial benefit and should be considered in allocation decisions about prevention.

Full text

PDF
1709

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Booth R. E., Watters J. K. How effective are risk-reduction interventions targeting injecting drug users? AIDS. 1994 Nov;8(11):1515–1524. doi: 10.1097/00002030-199411000-00001. [DOI] [PubMed] [Google Scholar]
  2. Choi K. H., Coates T. J. Prevention of HIV infection. AIDS. 1994 Oct;8(10):1371–1389. doi: 10.1097/00002030-199410000-00003. [DOI] [PubMed] [Google Scholar]
  3. Des Jarlais D. C., Friedman S. R., Sotheran J. L., Wenston J., Marmor M., Yancovitz S. R., Frank B., Beatrice S., Mildvan D. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA. 1994 Jan 12;271(2):121–127. [PubMed] [Google Scholar]
  4. Des Jarlais D. C., Hagan H., Friedman S. R., Friedmann P., Goldberg D., Frischer M., Green S., Tunving K., Ljungberg B., Wodak A. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995 Oct 18;274(15):1226–1231. doi: 10.1001/jama.274.15.1226. [DOI] [PubMed] [Google Scholar]
  5. Des Jarlais D. C., Padian N. S., Winkelstein W., Jr Targeted HIV-prevention programs. N Engl J Med. 1994 Nov 24;331(21):1451–1453. doi: 10.1056/NEJM199411243312112. [DOI] [PubMed] [Google Scholar]
  6. Friedman S. R., Des Jarlais D. C. HIV among drug injectors: the epidemic and the response. AIDS Care. 1991;3(3):239–250. doi: 10.1080/09540129108253069. [DOI] [PubMed] [Google Scholar]
  7. Holtgrave D. R., Qualls N. L., Curran J. W., Valdiserri R. O., Guinan M. E., Parra W. C. An overview of the effectiveness and efficiency of HIV prevention programs. Public Health Rep. 1995 Mar-Apr;110(2):134–146. [PMC free article] [PubMed] [Google Scholar]
  8. Lemp G. F., Hirozawa A. M., Givertz D., Nieri G. N., Anderson L., Lindegren M. L., Janssen R. S., Katz M. Seroprevalence of HIV and risk behaviors among young homosexual and bisexual men. The San Francisco/Berkeley Young Men's Survey. JAMA. 1994 Aug 10;272(6):449–454. [PubMed] [Google Scholar]
  9. Moss A. R., Vranizan K., Gorter R., Bacchetti P., Watters J., Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS. 1994 Feb;8(2):223–231. doi: 10.1097/00002030-199402000-00010. [DOI] [PubMed] [Google Scholar]
  10. Osmond D. H., Page K., Wiley J., Garrett K., Sheppard H. W., Moss A. R., Schrager L., Winkelstein W. HIV infection in homosexual and bisexual men 18 to 29 years of age: the San Francisco Young Men's Health Study. Am J Public Health. 1994 Dec;84(12):1933–1937. doi: 10.2105/ajph.84.12.1933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rogers D. E., Osborn J. E. AIDS policy. Two divisive issues. JAMA. 1993 Jul 28;270(4):494–495. [PubMed] [Google Scholar]
  12. Siegel J. E., Weinstein M. C., Fineberg H. V. Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence. Am J Public Health. 1991 Oct;81(10):1273–1279. doi: 10.2105/ajph.81.10.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Stryker J., Bayer R. AIDS policy: two divisive issues. JAMA. 1993 Nov 24;270(20):2436–2437. doi: 10.1001/jama.270.20.2436. [DOI] [PubMed] [Google Scholar]
  14. Vermund S. H. Decision making for clinical trials and prevention research: commentary on the model of Paltiel and Kaplan. J Acquir Immune Defic Syndr. 1993 Feb;6(2):176–178. [PubMed] [Google Scholar]
  15. Zolopa A. R., Hahn J. A., Gorter R., Miranda J., Wlodarczyk D., Peterson J., Pilote L., Moss A. R. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA. 1994 Aug 10;272(6):455–461. [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES